Copeptin - biochemistry and clinical diagnostics:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bremen ; London ; Boston
UNI-MED-Verlag
2014
|
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | 119 Seiten Illustrationen 25 cm |
| ISBN: | 9783837422863 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV047373746 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 210716s2014 gw a||| |||| 00||| eng d | ||
| 015 | |a 14,A48 |2 dnb | ||
| 016 | 7 | |a 1060234106 |2 DE-101 | |
| 020 | |a 9783837422863 |c Pp. : EUR 4.95 |9 978-3-8374-2286-3 | ||
| 035 | |a (DE-599)DNB1060234106 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-HB | ||
| 082 | 0 | |a 616.0756 |2 22/ger | |
| 084 | |a YI 5000 |0 (DE-625)153641:12905 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Copeptin - biochemistry and clinical diagnostics |c Nils G. Morgenthaler |
| 264 | 1 | |a Bremen ; London ; Boston |b UNI-MED-Verlag |c 2014 | |
| 300 | |a 119 Seiten |b Illustrationen |c 25 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 500 | |a Literaturangaben | ||
| 650 | 0 | 7 | |a Diagnostik |0 (DE-588)4113303-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Vasopressin |0 (DE-588)4138370-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biomarker |0 (DE-588)4425928-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Copeptin |0 (DE-588)1061014339 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Copeptin |0 (DE-588)1061014339 |D s |
| 689 | 0 | 1 | |a Biomarker |0 (DE-588)4425928-1 |D s |
| 689 | 0 | 2 | |a Vasopressin |0 (DE-588)4138370-9 |D s |
| 689 | 0 | 3 | |a Diagnostik |0 (DE-588)4113303-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Morgenthaler, Nils |0 (DE-588)113262884 |4 edt | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032775485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032775485 | ||
Datensatz im Suchindex
| _version_ | 1804182614195568640 |
|---|---|
| adam_text | 10 CONTENTS
CONTENTS
H AVP AND
COPEPTIN: RELATIONSHIP AND FUNCTION 16
1.1. STRUCTURE OF AVP AND COPEPTIN 16
1.2. SYNTHESIS OF AVP AND COPEPTIN 16
1.2.1. PRODUCTION IN MAGNOCELIULAR NEURONS AND STORAGE IN THE POSTERIOR
PITUITARY 16
1.2.2. PRODUCTION IN PARVOCELLULAR NEURONS AND RELEASE IN THE PORTAL
SYSTEM 17
1.3. AVP RECEPTORS AND THE AVP EFFECT 17
1.3.1. V,-RECEPTOR: VASOCONSTRICTION 17
1.3.2. VJ-RECEPTOR: WATER BALANCE 18
1.3.3. VJ-RECEPTOR: ACTH SECRETION 19
1.3.4. OTHER NON-SPECIFIC INTERACTIONS 19
1.4. PHYSIOLOGIC FUNCTION OF COPEPTIN 19
1.4.1. POTENTIAL ROLE AS A CHAPERONE 19
1.4.2. PERIPHERAL FUNCTION 19
1.5. REFERENCES 19
H MEASUREMENT OF AVP AND COPEPTIN 22
2.1. THE TROUBLE WITH MEASURING AVP 22
2.2. THE PROHORMONE ALTERNATIVE 22
2.3. MEASUREMENT OF COPEPTIN 22
2.3.1. COPEPTIN ASSAYS 23
2.3.2. ADVANTAGES OF MEASURING COPEPTIN 23
2.3.3. PRACTICAL AND ECONOMIC CONSIDERATIONS 24
2.4. REFERENCES 24
H COPEPTIN AND AVP IN SERUM: NORMAL VALUES AND PHYSIOLOGICAL RESPONSE 28
3.1. NORMAL RANGE OF COPEPTIN 28
3.2. INFLUENCE OF SERUM OSMOLALITY 28
3.3. INFLUENCE OF BLOOD PRESSURE 29
3.4. INFLUENCE OF EXERCISE 30
3.5. CORRELATION BETWEEN AVP AND COPEPTIN 30
3.6. CONCLUSION FOR THE CLINICIAN 30
3.7. REFERENCES 30
M COPEPTIN AND THE DIAGNOSIS OF DIABETES INSIPIDUS 34
4.1. DIABETES INSIPIDUS AND THE POLYURIA POLYDIPSIA SYNDROME 34
4.2. DIFFICULTIES IN THE DIAGNOSIS OF THE POLYURIA POLYDIPSIA SYNDROME
34
4.3. THE ROLE OF COPEPTIN IN THE DIAGNOSIS 35
4.3.1. PROOF-OF-CONCEPT STUDY 35
4.3.2. FURTHER CLINICAL STUDIES 36
4.4. INTEGRATION OF COPEPTIN IN THE WORKFLOW 36
4.5. CONCLUSION 37
4.6. REFERENCES 37
HTTP://D-NB.INFO/1060234106
CONTENTS 11
|
COPEPTIN IN HYPONATREMIA 40
5.1. ELECTROLYTE DISTURBANCES 40
5.1.1. HYPONATREMIA 40
5.1.2. SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (SIADH)
41
5.1.3. DIFFERENT CAUSES OF HYPONATREMIA 42
5.2. DIAGNOSTIC VALUE OF COPEPTIN IN HYPONATREMIA 43
5.2.1. OBSERVATIONAL STUDY IN PATIENTS WITH ELECTROLYTE DISTURBANCES 43
5.2.2. COPEPTIN AND DISTURBED SODIUM BALANCE IN ACUTELY ILL PATIENTS 43
5.2.3. COPEPTIN AND SIAD IN ONCOLOGICAL PATIENTS 44
5.3. AVP-RECEPTOR ANTAGONISTS (VAPTANS) 45
5.4. CONCLUSION 46
5.5. REFERENCES 46
M COPEPTIN IN ACUTE MYOCARDIAL INFARCTION 50
6.1. THE CLINICAL NEED 50
6.1.1. DIAGNOSIS 50
6.1.2. PROGNOSIS 51
6.2. COPEPTIN FOR THE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION 52
6.2.1. THE RIGHT CUT-OFF FOR COPEPTIN: 10 PMOL/L 52
6.2.2. COPEPTIN IN AMI INCREASES EARLY AND DECLINES FAST 53
6.2.3. LOW TO INTERMEDIATE RISK PATIENTS BENEFIT MOST 53
6.2.4. CLINICAL APPLICATION 53
6.2.5. CONCLUSION 54
6.3. SPECIAL ASPECTS OF CLINICAL PRACTICE 54
6.4. PROCEDURAL BENEFITS FOR THE PATIENT FLOW USING COPEPTIN 56
6.5. COPEPTIN FOR PROGNOSIS IN AMI 56
6.5.1. PROGNOSTIC VALUE OF COPEPTIN 56
6.5.2. CONCLUSION 57
6.6. REFERENCES 57
|
COPEPTIN AND THE HEART FAILURE SYNDROME 62
7.1. HEART FAILURE AS AN ENDOCRINE DISEASE 62
7.2. ROLEOFAVP IN HEART FAILURE 62
7.3. COPEPTIN BEFORE HEART FAILURE 62
7.3.1. HEART FAILURE AS A RESULT OF MYOCARDIAL INFARCTION 62
7.3.2. HEART FAILURE DUE TO OTHER REASONS 63
7.4. COPEPTIN IN HEART FAILURE DIAGNOSIS 63
7.5. COPEPTIN IN HEART FAILURE PATIENTS 63
7.6. ANTI-VASOPRESSIN TREATMENT IN HEART FAILURE AND COPEPTIN 65
7.7. COPEPTIN AND OTHER CONDITIONS 66
7.8. COPEPTIN, HEART FAILURE AND THE NEAR FUTURE 66
7.9. COPEPTIN IN HEART FAILURE: A CONTEMPORARY CONCLUSION 66
7.10. REFERENCES 67
12 CONTENTS
| COPEPTIN IN CEREBROVASCULAR DISEASE 70
8.1. INTRODUCTION 70
8.1.1. THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS AND STROKE 70
8.1.2. COPEPTIN - A HYPOTHALAMIC STRESS HORMONE 70
8.1.3. HYPOTHESIS BEHIND THE LINK OF COPEPTIN AND STROKE OUTCOME 71
8.2. COPEPTIN IN ACUTE ISCHEMIC STROKE 72
8.2.1. BACKGROUND 72
8.2.2. COPEPTIN AS A PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY 72
8.2.2.1. THE COSMOS STUDY 72
8.2.2.2. THE CORISK STUDY 73
8.2.2.3. OTHER STUDIES 74
8.2.3. COPEPTIN AS A MARKER OF COMPLICATIONS AFTER STROKE 74
8.3. COPEPTIN IN PATIENTS WITH TRANSIENT ISCHEMIC ATTACKS (TIA) 75
8.3.1. BACKGROUND 75
8.3.2. COPEPTIN AND RISK STRATIFICATION IN TIA PATIENTS 75
8.4. COPEPTIN AND INTRACEREBRAL HAEMORRHAGE (ICH) OR SUBARACHNOID
HAEMORRHAGE (SAH) 76
8.4.1. BACKGROUND 76
8.4.2. COPEPTIN AS PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY IN ICH 77
8.4.3. COPEPTIN AS PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY IN SAH 77
8.5. SUMMARY AND PERSPECTIVES 78
8.6. REFERENCES 78
M COPEPTIN IN CRITICALLY ILL PATIENTS 82
9.1. INTRODUCTION 82
9.1.1. THE ROLE OF AVP IN MAINTAINING BLOOD PRESSURE 82
9.1.2. VASOPRESSIN V,-RECEPTOR ACTION AND THERAPEUTIC USE OF AVP 82
9.1.3. VALUE OF AVP DETERMINATION IN CRITICALLY ILL PATIENTS 82
9.1.4. COPEPTIN AS A SURROGATE MARKER 82
9.2. COPEPTIN IN A MIXED POPULATION OF CRITICALLY ILL PATIENTS AND IN
HEALTHY VOLUNTEERS 82
9.3. COPEPTIN IN CARDIAC SURGERY 83
9.3.1. COPEPTIN IN PATIENTS WITH SHOCK AFTER CARDIAC SURGERY 83
9.3.2. COPEPTIN AFTER ELECTIVE CARDIAC SURGERY 84
9.3.3. COPEPTIN AND CARDIAC SURGERY IN CHILDREN 84
9.4. COPEPTIN AFTER NON-CARDIAC SURGERY IN PATIENTS WITH SIRS AND SHOCK
85
9.5. PATIENTS IN SEPSIS AND HEMORRHAGIC SHOCK 85
9.5.1. AVP AND COPEPTIN IN A SEPTIC PATIENT 85
9.5.2. ADULT PATIENTS WITH SEPSIS, SEVERE SEPSIS OR SEPTIC SHOCK 86
9.5.3. CHILDREN WITH SEPSIS, SEVERE SEPSIS OR SEPTIC SHOCK 87
9.5.4. COPEPTIN IN HEMORRHAGIC SHOCK IN A BABOON MODEL 87
9.6. COPEPTIN BEFORE AND DURING INFUSION OF AVP IN VASODILATORY SHOCK 87
9.7. AVP AND COPEPTIN IN PATIENTS WITH TRAUMA 88
9.7.1. AVP AND COPEPTIN IN POLYTRAUMA 88
9.7.2. COPEPTIN IN TRAUMATIC BRAIN INJURY (TBI) 89
9.8. SUMMARY 90
9.9. REFERENCES 90
CONTENTS 13
COPEPTIN IN THE EMERGENCY DEPARTMENT (ED) 94
10.1. COPEPTIN MEASUREMENT IN ED PATIENTS WITH DYSPNEA, LOWER
RESPIRATORY TRACT INFECTION
AND COPD 94
10.1.1. DYSPNEA 94
10.1.2. LOWER RESPIRATORY TRACT INFECTION 95
10.1.3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 96
10.2. COPEPTIN MEASUREMENT IN A HIGH RISK GERIATRIC POPULATION WITH
NON-SPECIFIC COMPLAINTS ... 96
10.3. OTHER POTENTIAL INDICATIONS FOR COPEPTIN MEASUREMENT 98
10.3.1. ACUTE PANCREATITIS 98
10.3.2. OUTCOME PREDICTION IN OUT-OF-HOSPITAL CARDIAC ARREST SURVIVORS
TREATED WITH THERAPEUTIC
HYPOTHERMIA * 98
10.3.3. TRAUMATIC BRAIN INJURY 98
10.4. CONCLUSION 99
10.5. REFERENCES 99
COPEPTIN IN NEONATES 102
11.1. INTRODUCTION TO BIRTH 102
11.2. THE DOMINANT ROLE OF THE MODE OF DELIVERY ON COPEPTIN 102
11.3. COPEPTIN AND INTRAUTERINE GROWTH RESTRICTION 103
11.4. DEPENDENCIES OF COPEPTIN DURING EARLY POSTNATAL LIFE 103
11.5. REASONS FOR HIGH COPEPTIN AT BIRTH 104
11.6. CONSEQUENCES OF HIGH VASOPRESSIN/COPEPTIN AT BIRTH 105
11.7. SUMMARY 106
11.8. REFERENCES 106
| COPEPTIN IN CHRONIC KIDNEY DISEASE AND ESPECIALLY AUTOSOMAL DOMINANT
POLYCYSTIC KIDNEY DISEASE 108
12.1. AVP AND COPEPTIN IN CHRONIC KIDNEY DISEASE 108
12.1.1. THE ROLE OF AVP IN EXPERIMENTAL CKD MODELS 108
12.1.2. THE ROLE OF AVP AND COPEPTIN IN HUMAN CKD 108
12.2. AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 109
12.2.1. AVP AND COPEPTIN IN ADPKD 110
12.2.2. CAUSE OF AVP INCREASE IN ADPKD 111
12.2.3. AVP ANTAGONISTS, PROMISING TREATMENT IN ADPKD 112
12.3. LOWERING AVP AND COPEPTIN LEVEL 112
12.3.1. WATER INTAKE AND AVP LEVEL 112
12.3.2. OSMOLAR INTAKE AND AVP LEVEL 113
12.3.3. OTHER LIFE STYLE FACTORS AND AVP LEVELS 113
12.4. POTENTIAL RELEVANCE OF MEASURING COPEPTIN IN CKD PATIENTS 113
12.5. CONCLUSIONS 114
12.6. REFERENCES 114
H INDEX 118
|
| adam_txt |
10 CONTENTS
CONTENTS
H AVP AND
COPEPTIN: RELATIONSHIP AND FUNCTION 16
1.1. STRUCTURE OF AVP AND COPEPTIN 16
1.2. SYNTHESIS OF AVP AND COPEPTIN 16
1.2.1. PRODUCTION IN MAGNOCELIULAR NEURONS AND STORAGE IN THE POSTERIOR
PITUITARY 16
1.2.2. PRODUCTION IN PARVOCELLULAR NEURONS AND RELEASE IN THE PORTAL
SYSTEM 17
1.3. AVP RECEPTORS AND THE AVP EFFECT 17
1.3.1. V,-RECEPTOR: VASOCONSTRICTION 17
1.3.2. VJ-RECEPTOR: WATER BALANCE 18
1.3.3. VJ-RECEPTOR: ACTH SECRETION 19
1.3.4. OTHER NON-SPECIFIC INTERACTIONS 19
1.4. PHYSIOLOGIC FUNCTION OF COPEPTIN 19
1.4.1. POTENTIAL ROLE AS A CHAPERONE 19
1.4.2. PERIPHERAL FUNCTION 19
1.5. REFERENCES 19
H MEASUREMENT OF AVP AND COPEPTIN 22
2.1. THE TROUBLE WITH MEASURING AVP 22
2.2. THE PROHORMONE ALTERNATIVE 22
2.3. MEASUREMENT OF COPEPTIN 22
2.3.1. COPEPTIN ASSAYS 23
2.3.2. ADVANTAGES OF MEASURING COPEPTIN 23
2.3.3. PRACTICAL AND ECONOMIC CONSIDERATIONS 24
2.4. REFERENCES 24
H COPEPTIN AND AVP IN SERUM: NORMAL VALUES AND PHYSIOLOGICAL RESPONSE 28
3.1. NORMAL RANGE OF COPEPTIN 28
3.2. INFLUENCE OF SERUM OSMOLALITY 28
3.3. INFLUENCE OF BLOOD PRESSURE 29
3.4. INFLUENCE OF EXERCISE 30
3.5. CORRELATION BETWEEN AVP AND COPEPTIN 30
3.6. CONCLUSION FOR THE CLINICIAN 30
3.7. REFERENCES 30
M COPEPTIN AND THE DIAGNOSIS OF DIABETES INSIPIDUS 34
4.1. DIABETES INSIPIDUS AND THE POLYURIA POLYDIPSIA SYNDROME 34
4.2. DIFFICULTIES IN THE DIAGNOSIS OF THE POLYURIA POLYDIPSIA SYNDROME
34
4.3. THE ROLE OF COPEPTIN IN THE DIAGNOSIS 35
4.3.1. PROOF-OF-CONCEPT STUDY 35
4.3.2. FURTHER CLINICAL STUDIES 36
4.4. INTEGRATION OF COPEPTIN IN THE WORKFLOW 36
4.5. CONCLUSION 37
4.6. REFERENCES 37
HTTP://D-NB.INFO/1060234106
CONTENTS 11
|
COPEPTIN IN HYPONATREMIA 40
5.1. ELECTROLYTE DISTURBANCES 40
5.1.1. HYPONATREMIA 40
5.1.2. SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (SIADH)
41
5.1.3. DIFFERENT CAUSES OF HYPONATREMIA 42
5.2. DIAGNOSTIC VALUE OF COPEPTIN IN HYPONATREMIA 43
5.2.1. OBSERVATIONAL STUDY IN PATIENTS WITH ELECTROLYTE DISTURBANCES 43
5.2.2. COPEPTIN AND DISTURBED SODIUM BALANCE IN ACUTELY ILL PATIENTS 43
5.2.3. COPEPTIN AND SIAD IN ONCOLOGICAL PATIENTS 44
5.3. AVP-RECEPTOR ANTAGONISTS (VAPTANS) 45
5.4. CONCLUSION 46
5.5. REFERENCES 46
M COPEPTIN IN ACUTE MYOCARDIAL INFARCTION 50
6.1. THE CLINICAL NEED 50
6.1.1. DIAGNOSIS 50
6.1.2. PROGNOSIS 51
6.2. COPEPTIN FOR THE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION 52
6.2.1. THE RIGHT CUT-OFF FOR COPEPTIN: 10 PMOL/L 52
6.2.2. COPEPTIN IN AMI INCREASES EARLY AND DECLINES FAST 53
6.2.3. LOW TO INTERMEDIATE RISK PATIENTS BENEFIT MOST 53
6.2.4. CLINICAL APPLICATION 53
6.2.5. CONCLUSION 54
6.3. SPECIAL ASPECTS OF CLINICAL PRACTICE 54
6.4. PROCEDURAL BENEFITS FOR THE PATIENT FLOW USING COPEPTIN 56
6.5. COPEPTIN FOR PROGNOSIS IN AMI 56
6.5.1. PROGNOSTIC VALUE OF COPEPTIN 56
6.5.2. CONCLUSION 57
6.6. REFERENCES 57
|
COPEPTIN AND THE HEART FAILURE SYNDROME 62
7.1. HEART FAILURE AS AN ENDOCRINE DISEASE 62
7.2. ROLEOFAVP IN HEART FAILURE 62
7.3. COPEPTIN BEFORE HEART FAILURE 62
7.3.1. HEART FAILURE AS A RESULT OF MYOCARDIAL INFARCTION 62
7.3.2. HEART FAILURE DUE TO OTHER REASONS 63
7.4. COPEPTIN IN HEART FAILURE DIAGNOSIS 63
7.5. COPEPTIN IN HEART FAILURE PATIENTS 63
7.6. ANTI-VASOPRESSIN TREATMENT IN HEART FAILURE AND COPEPTIN 65
7.7. COPEPTIN AND OTHER CONDITIONS 66
7.8. COPEPTIN, HEART FAILURE AND THE NEAR FUTURE 66
7.9. COPEPTIN IN HEART FAILURE: A CONTEMPORARY CONCLUSION 66
7.10. REFERENCES 67
12 CONTENTS
| COPEPTIN IN CEREBROVASCULAR DISEASE 70
8.1. INTRODUCTION 70
8.1.1. THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS AND STROKE 70
8.1.2. COPEPTIN - A HYPOTHALAMIC STRESS HORMONE 70
8.1.3. HYPOTHESIS BEHIND THE LINK OF COPEPTIN AND STROKE OUTCOME 71
8.2. COPEPTIN IN ACUTE ISCHEMIC STROKE 72
8.2.1. BACKGROUND 72
8.2.2. COPEPTIN AS A PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY 72
8.2.2.1. THE COSMOS STUDY 72
8.2.2.2. THE CORISK STUDY 73
8.2.2.3. OTHER STUDIES 74
8.2.3. COPEPTIN AS A MARKER OF COMPLICATIONS AFTER STROKE 74
8.3. COPEPTIN IN PATIENTS WITH TRANSIENT ISCHEMIC ATTACKS (TIA) 75
8.3.1. BACKGROUND 75
8.3.2. COPEPTIN AND RISK STRATIFICATION IN TIA PATIENTS 75
8.4. COPEPTIN AND INTRACEREBRAL HAEMORRHAGE (ICH) OR SUBARACHNOID
HAEMORRHAGE (SAH) 76
8.4.1. BACKGROUND 76
8.4.2. COPEPTIN AS PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY IN ICH 77
8.4.3. COPEPTIN AS PROGNOSTIC MARKER FOR FUNCTIONAL OUTCOME AND
MORTALITY IN SAH 77
8.5. SUMMARY AND PERSPECTIVES 78
8.6. REFERENCES 78
M COPEPTIN IN CRITICALLY ILL PATIENTS 82
9.1. INTRODUCTION 82
9.1.1. THE ROLE OF AVP IN MAINTAINING BLOOD PRESSURE 82
9.1.2. VASOPRESSIN V,-RECEPTOR ACTION AND THERAPEUTIC USE OF AVP 82
9.1.3. VALUE OF AVP DETERMINATION IN CRITICALLY ILL PATIENTS 82
9.1.4. COPEPTIN AS A SURROGATE MARKER 82
9.2. COPEPTIN IN A MIXED POPULATION OF CRITICALLY ILL PATIENTS AND IN
HEALTHY VOLUNTEERS 82
9.3. COPEPTIN IN CARDIAC SURGERY 83
9.3.1. COPEPTIN IN PATIENTS WITH SHOCK AFTER CARDIAC SURGERY 83
9.3.2. COPEPTIN AFTER ELECTIVE CARDIAC SURGERY 84
9.3.3. COPEPTIN AND CARDIAC SURGERY IN CHILDREN 84
9.4. COPEPTIN AFTER NON-CARDIAC SURGERY IN PATIENTS WITH SIRS AND SHOCK
85
9.5. PATIENTS IN SEPSIS AND HEMORRHAGIC SHOCK 85
9.5.1. AVP AND COPEPTIN IN A SEPTIC PATIENT 85
9.5.2. ADULT PATIENTS WITH SEPSIS, SEVERE SEPSIS OR SEPTIC SHOCK 86
9.5.3. CHILDREN WITH SEPSIS, SEVERE SEPSIS OR SEPTIC SHOCK 87
9.5.4. COPEPTIN IN HEMORRHAGIC SHOCK IN A BABOON MODEL 87
9.6. COPEPTIN BEFORE AND DURING INFUSION OF AVP IN VASODILATORY SHOCK 87
9.7. AVP AND COPEPTIN IN PATIENTS WITH TRAUMA 88
9.7.1. AVP AND COPEPTIN IN POLYTRAUMA 88
9.7.2. COPEPTIN IN TRAUMATIC BRAIN INJURY (TBI) 89
9.8. SUMMARY 90
9.9. REFERENCES 90
CONTENTS 13
COPEPTIN IN THE EMERGENCY DEPARTMENT (ED) 94
10.1. COPEPTIN MEASUREMENT IN ED PATIENTS WITH DYSPNEA, LOWER
RESPIRATORY TRACT INFECTION
AND COPD 94
10.1.1. DYSPNEA 94
10.1.2. LOWER RESPIRATORY TRACT INFECTION 95
10.1.3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 96
10.2. COPEPTIN MEASUREMENT IN A HIGH RISK GERIATRIC POPULATION WITH
NON-SPECIFIC COMPLAINTS . 96
10.3. OTHER POTENTIAL INDICATIONS FOR COPEPTIN MEASUREMENT 98
10.3.1. ACUTE PANCREATITIS 98
10.3.2. OUTCOME PREDICTION IN OUT-OF-HOSPITAL CARDIAC ARREST SURVIVORS
TREATED WITH THERAPEUTIC
HYPOTHERMIA * 98
10.3.3. TRAUMATIC BRAIN INJURY 98
10.4. CONCLUSION 99
10.5. REFERENCES 99
COPEPTIN IN NEONATES 102
11.1. INTRODUCTION TO BIRTH 102
11.2. THE DOMINANT ROLE OF THE MODE OF DELIVERY ON COPEPTIN 102
11.3. COPEPTIN AND INTRAUTERINE GROWTH RESTRICTION 103
11.4. DEPENDENCIES OF COPEPTIN DURING EARLY POSTNATAL LIFE 103
11.5. REASONS FOR HIGH COPEPTIN AT BIRTH 104
11.6. CONSEQUENCES OF HIGH VASOPRESSIN/COPEPTIN AT BIRTH 105
11.7. SUMMARY 106
11.8. REFERENCES 106
| COPEPTIN IN CHRONIC KIDNEY DISEASE AND ESPECIALLY AUTOSOMAL DOMINANT
POLYCYSTIC KIDNEY DISEASE 108
12.1. AVP AND COPEPTIN IN CHRONIC KIDNEY DISEASE 108
12.1.1. THE ROLE OF AVP IN EXPERIMENTAL CKD MODELS 108
12.1.2. THE ROLE OF AVP AND COPEPTIN IN HUMAN CKD 108
12.2. AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 109
12.2.1. AVP AND COPEPTIN IN ADPKD 110
12.2.2. CAUSE OF AVP INCREASE IN ADPKD 111
12.2.3. AVP ANTAGONISTS, PROMISING TREATMENT IN ADPKD 112
12.3. LOWERING AVP AND COPEPTIN LEVEL 112
12.3.1. WATER INTAKE AND AVP LEVEL 112
12.3.2. OSMOLAR INTAKE AND AVP LEVEL 113
12.3.3. OTHER LIFE STYLE FACTORS AND AVP LEVELS 113
12.4. POTENTIAL RELEVANCE OF MEASURING COPEPTIN IN CKD PATIENTS 113
12.5. CONCLUSIONS 114
12.6. REFERENCES 114
H INDEX 118 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Morgenthaler, Nils |
| author2_role | edt |
| author2_variant | n m nm |
| author_GND | (DE-588)113262884 |
| author_facet | Morgenthaler, Nils |
| building | Verbundindex |
| bvnumber | BV047373746 |
| classification_rvk | YI 5000 |
| ctrlnum | (DE-599)DNB1060234106 |
| dewey-full | 616.0756 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.0756 |
| dewey-search | 616.0756 |
| dewey-sort | 3616.0756 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01761nam a2200457 c 4500</leader><controlfield tag="001">BV047373746</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">210716s2014 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">14,A48</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1060234106</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837422863</subfield><subfield code="c">Pp. : EUR 4.95</subfield><subfield code="9">978-3-8374-2286-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1060234106</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-HB</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.0756</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YI 5000</subfield><subfield code="0">(DE-625)153641:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Copeptin - biochemistry and clinical diagnostics</subfield><subfield code="c">Nils G. Morgenthaler</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED-Verlag</subfield><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">119 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">25 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Diagnostik</subfield><subfield code="0">(DE-588)4113303-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Vasopressin</subfield><subfield code="0">(DE-588)4138370-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Copeptin</subfield><subfield code="0">(DE-588)1061014339</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Copeptin</subfield><subfield code="0">(DE-588)1061014339</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Biomarker</subfield><subfield code="0">(DE-588)4425928-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Vasopressin</subfield><subfield code="0">(DE-588)4138370-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Diagnostik</subfield><subfield code="0">(DE-588)4113303-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morgenthaler, Nils</subfield><subfield code="0">(DE-588)113262884</subfield><subfield code="4">edt</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032775485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032775485</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV047373746 |
| illustrated | Illustrated |
| index_date | 2024-07-03T17:45:41Z |
| indexdate | 2024-07-10T09:10:21Z |
| institution | BVB |
| isbn | 9783837422863 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032775485 |
| open_access_boolean | |
| physical | 119 Seiten Illustrationen 25 cm |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | UNI-MED-Verlag |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Copeptin - biochemistry and clinical diagnostics Nils G. Morgenthaler Bremen ; London ; Boston UNI-MED-Verlag 2014 119 Seiten Illustrationen 25 cm txt rdacontent n rdamedia nc rdacarrier UNI-MED science Literaturangaben Diagnostik (DE-588)4113303-1 gnd rswk-swf Vasopressin (DE-588)4138370-9 gnd rswk-swf Biomarker (DE-588)4425928-1 gnd rswk-swf Copeptin (DE-588)1061014339 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Copeptin (DE-588)1061014339 s Biomarker (DE-588)4425928-1 s Vasopressin (DE-588)4138370-9 s Diagnostik (DE-588)4113303-1 s DE-604 Morgenthaler, Nils (DE-588)113262884 edt DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032775485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Copeptin - biochemistry and clinical diagnostics Diagnostik (DE-588)4113303-1 gnd Vasopressin (DE-588)4138370-9 gnd Biomarker (DE-588)4425928-1 gnd Copeptin (DE-588)1061014339 gnd |
| subject_GND | (DE-588)4113303-1 (DE-588)4138370-9 (DE-588)4425928-1 (DE-588)1061014339 (DE-588)4143413-4 |
| title | Copeptin - biochemistry and clinical diagnostics |
| title_auth | Copeptin - biochemistry and clinical diagnostics |
| title_exact_search | Copeptin - biochemistry and clinical diagnostics |
| title_exact_search_txtP | Copeptin - biochemistry and clinical diagnostics |
| title_full | Copeptin - biochemistry and clinical diagnostics Nils G. Morgenthaler |
| title_fullStr | Copeptin - biochemistry and clinical diagnostics Nils G. Morgenthaler |
| title_full_unstemmed | Copeptin - biochemistry and clinical diagnostics Nils G. Morgenthaler |
| title_short | Copeptin - biochemistry and clinical diagnostics |
| title_sort | copeptin biochemistry and clinical diagnostics |
| topic | Diagnostik (DE-588)4113303-1 gnd Vasopressin (DE-588)4138370-9 gnd Biomarker (DE-588)4425928-1 gnd Copeptin (DE-588)1061014339 gnd |
| topic_facet | Diagnostik Vasopressin Biomarker Copeptin Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032775485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT morgenthalernils copeptinbiochemistryandclinicaldiagnostics |